中国中药(00570)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

00570 中国中药

休市中 09-25 16:08:14

1.215

-0.045

-3.57%

最高1.265	最低1.210	成交量310.40万
今开1.255	昨收1.260	日振幅4.37%
总市值61.19亿	流通市值61.18亿	总股本50.36亿
成交额378.38万	换手率0.06%	流通股本50.36亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"00570","market":"HK","secType":"STK","nameCN":"中国中药","latestPrice":1.215,"timestamp":1790323694003,"preClose":1.26,"halted":0,"volume":3104000,"delay":0,"changeRate":-0.03571428571428566,"floatShares":5035801852,"shares":5036000000,"eps":-0.07918302600101965,"marketStatus":"休市中","change":-0.045,"latestTime":"09-25 16:08:14","open":1.255,"high":1.265,"low":1.21,"amount":3783751,"amplitude":0.043651,"askPrice":1.22,"askSize":12000,"bidPrice":1.215,"bidSize":128000,"shortable":3,"etf":0,"ttmEps":-0.2341940033962116,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1790559000000},"marketStatusCode":7,"adr":0,"listingDate":734112000000,"exchange":"SEHK","adjPreClose":1.26,"openAndCloseTimeList":[[1790299800000,1790308800000],[1790312400000,1790323200000]],"volumeRatio":0.14520459214829934,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/00570","defaultTab":"news","newsList":[{"id":"2667642784","title":"中国中药(00570.HK)附属签订车间改造项目工程总承包合同及产能提升技术改造项目工程总承包合同","url":"https://stock-news.laohu8.com/highlight/detail?id=2667642784","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667642784?lang=zh_cn&edition=full","pubTime":"2026-09-15 20:32","pubTimestamp":1789475579,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["00570","BK1606","BK1191","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147670501","title":"中国中药子公司签逾2,190万元改扩建合同 涉关连交易免独立股东批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1147670501","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1147670501?lang=zh_cn&edition=full","pubTime":"2026-09-15 20:32","pubTimestamp":1789475521,"startTime":"0","endTime":"0","summary":"2026年9月15日，中国中药控股有限公司公告称，其全资附属公司山东一方制药有限公司及国药集团中联药业有限公司分别与中国医药集团联合工程有限公司签订工程总承包合同，合计金额约2,190.58万元，构成关连交易。公司表示，上述改造及产能提升项目旨在补充山东一方中药饮片产能、提升中联药业异维A酸红霉素凝胶等产品产能，并改善安全及设施条件，以满足市场需求。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00570"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102382871","title":"中国中药旗下子公司签约山东益方改造项目，合同金额1060万元及其他事项","url":"https://stock-news.laohu8.com/highlight/detail?id=1102382871","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1102382871?lang=zh_cn&edition=full","pubTime":"2026-09-15 20:31","pubTimestamp":1789475470,"startTime":"0","endTime":"0","summary":"中国中药发布公告称，其子公司精方药业已就山东益方改造项目达成承包协议。该项目合同总金额为人民币1060万元。值得注意的是，此次签约标志着公司在区域业务拓展上迈出了新的一步。除这一核心项目外，公告还披露了其他相关事项，进一步丰富了本次信息披露的内容维度。需关注的是，合同履行过程中仍存在原材料价格波动、施工进度不确定性等潜在风险因素。公司表示，将严格按照合同条款推进项目执行，确保按期保质完成各项建设任务。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1606","00570","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127368113","title":"中国中药（00570）1.1类中药创新药“醒脾解郁片”获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1127368113","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1127368113?lang=zh_cn&edition=full","pubTime":"2026-09-04 20:51","pubTimestamp":1788526274,"startTime":"0","endTime":"0","summary":"2026年9月4日，中国中药控股有限公司发布自愿性公告称，其附属公司国药集团同济堂（贵州）制药有限公司申报的1.1类中药创新药“醒脾解郁片”已获国家药品监督管理局批准上市，药品上市许可持有人为同济堂制药。该药品为此前公告中的“郁枢达片”，此次获批系国家药监局完成技术审评、现场核查及抽样检验后所作决定。公告显示，“醒脾解郁片”主要功效为醒脾化湿、理气解郁，适用于轻、中度抑郁症患者。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00570"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664334496","title":"中国中药(00570)：1.1类中药创新药醒脾解郁片获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2664334496","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664334496?lang=zh_cn&edition=full","pubTime":"2026-09-04 20:50","pubTimestamp":1788526251,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国中药(00570)发布公告，有关国家药监局受理集团的附属公司国药集团同济堂（贵州）制药有限公司（同济堂制药）的1.1类中药创新药郁枢达片注册上市申请。经国家药监局完成技术审评、现场核查、抽样检验等一系列工作程序，同济堂制药申报的1.1类中药创新药醒脾解郁片（即先前公告所称“郁枢达片”，为该药品获国家药监局核准的规范通用名称）已获得批准上市，药品上市许可持有人为同济堂制药。醒脾解郁片具有醒脾化湿、理气解郁的功效，用于轻、中度抑郁症，症状为情绪郁闷、低落，表情淡漠、倦怠乏力、失眠多梦、少气懒言、食少纳呆，头重肢困、 口中黏腻、面色晦暗，舌淡苔白腻或灰腻、脉滑或弦。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492351.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","LNGR","BK1606","IPOS","MEDX","BK1191","BK1574","159992","00570","BK1515","IBBQ","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140699022","title":"中国中药8月股份变动月报表：股本保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1140699022","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1140699022?lang=zh_cn&edition=full","pubTime":"2026-09-01 17:35","pubTimestamp":1788255339,"startTime":"0","endTime":"0","summary":"中国中药（00570）于2026年9月1日向香港联交所提交2026年8月31日止股份变动月报表。报告显示，截至本月末，公司普通股已发行股份维持5,035,801,852股，库存股份数量为0，与上月底持平。\n月报中未披露任何新增发行、购回或注销股份情况，也未列示任何与期权或股权激励计划相关的变动。有关注意事项包括：公司确认其公开发售股份比例符合适用的最低公众持股量要求。报告另无涉及公司发行人股份的其他回复、权证或可换股票据的订立、行使及注销等安排。\n公告显示，中国中药继续遵守香港联交所《上市规则》和相关法律规定，其股本结构在当月保持不变。该公告由公司秘书伍秀薇签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00570"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662093482","title":"中国中药(00570)发布中期业绩 股东应占亏损7.76亿元 同比扩大619.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662093482","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662093482?lang=zh_cn&edition=full","pubTime":"2026-08-28 20:56","pubTimestamp":1787921819,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国中药(00570)发布截至2026年6月30日止6个月中期业绩，营业额54.38亿元(人民币，下同)，同比减少27.1%;股东应占亏损7.76亿元，同比扩大619.3%;每股基本亏损15.42分。公告称，报告期内，集团营业收入同比下降27.1%，主要是中药配方颗粒业务受行业政策调整及市场环境变化的影响，终端需求下降，本期销量减少。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1488397.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1606","00570","BK1191","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103049295","title":"中国中药2026年上半年营收54.38亿元，经调整净亏损7.76亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1103049295","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1103049295?lang=zh_cn&edition=full","pubTime":"2026-08-28 20:13","pubTimestamp":1787919208,"startTime":"0","endTime":"0","summary":"中国中药公告显示，2026年上半年公司实现营收54.38亿元，同比下降27.1%。经调整净亏损7.76亿元，同比下降619.3%。毛利25.81亿元，较去年同期下滑29.0%，毛利率约为47.5%，较去年同期下降1.2个百分点。中药材生产及经营：营收1.90亿元，同比下降57.5%，毛利率4.8%，较上年同期减少5.0个百分点。中医药大健康：营收0.93亿元，同比下降23.5%，毛利率33.8%，同比上升3.0个百分点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"中国中药2026年上半年营收54.38亿元，经调整净亏损7.76亿元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00570"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123509844","title":"中国中药（00570）将于8月28日召开董事会审议2026年中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1123509844","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123509844?lang=zh_cn&edition=full","pubTime":"2026-08-18 17:01","pubTimestamp":1787043661,"startTime":"0","endTime":"0","summary":"中国中药（00570）8月18日公告称，公司董事会会议定于2026年8月28日（星期五）举行，届时将审议并批准公司及其附属公司截至2026年6月30日止六个月的中期业绩并对外发布。该次会议亦将处理其他董事会常规事务。\n公告显示，公司董事会目前共有12名成员，包括3名执行董事（郭晋红、李鸿坚及彭力），5名非执行董事（李向荣、祖敬、许京辉、陈坤及黄灝），以及4名独立非执行董事（谢荣、余梓山、秦岭及李伟东）。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00570"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158793561","title":"中国中药7月股份变动月报：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1158793561","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1158793561?lang=zh_cn&edition=full","pubTime":"2026-08-03 16:57","pubTimestamp":1785747449,"startTime":"0","endTime":"0","summary":"2026年8月3日，中国中药（00570）发布2026年7月股份变动月报。公告显示，截至2026年7月31日，公司已发行股份（不包括库存股份）5,035,801,852股，库存股份为0股，已发行股份总数同样为5,035,801,852股，当月无新增发行、购买或注销，股本结构维持平稳。\n公告同时显示，公司已确认满足香港联交所规定的最低公众持股量要求。未见关于股份期权、股权激励计划或其他相关协议的变动信息。\n本次公告由公司秘书伍秀薇于2026年8月3日签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00570"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652391261","title":"港股异动 | 中国中药(00570.HK)盈警后跌超7% 预计上半年亏损约8亿元至8.5亿元 业态影响导致公司商誉减值","url":"https://stock-news.laohu8.com/highlight/detail?id=2652391261","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652391261?lang=zh_cn&edition=full","pubTime":"2026-07-20 11:17","pubTimestamp":1784517461,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1606","BK1515","BK1191","00570"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652128681","title":"中国中药(00570)发盈警 预计上半年亏损约8亿元至8.5亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2652128681","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652128681?lang=zh_cn&edition=full","pubTime":"2026-07-17 21:35","pubTimestamp":1784295329,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国中药 发布公告，预期集团截至2026年6月30日止六个月亏损约为人民币8亿元至8.5亿元，去年同期亏损约人民币1.42亿元。董事会强调，上述商誉减值属非现金性质，乃为使集团财务状况未来可取得改善而采取的必要措施。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469287.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"中国中药(00570)发盈警 预计上半年亏损约8亿元至8.5亿元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00570","BK1606","BK1515","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176450848","title":"中国中药(00570)发布盈利预警：上半年预亏约8亿元至8.5亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1176450848","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176450848?lang=zh_cn&edition=full","pubTime":"2026-07-17 21:30","pubTimestamp":1784295051,"startTime":"0","endTime":"0","summary":"中国中药控股有限公司 7月17日公告，根据未经审计的综合管理账目初步评估，预计截至2026年6月30日止六个月将录得净亏损约8亿元至8.5亿元；上年同期亏损约1.42亿元。\\n\\n公告称，上述商誉减值为非现金性质。\\n\\n公司计划于2026年8月底前披露截至2026年6月30日止六个月的中期业绩。公司提醒股东及潜在投资者在买卖公司股份时保持审慎。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00570"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146526446","title":"中国中药（00570）公布董事会成员及委员会职务分配","url":"https://stock-news.laohu8.com/highlight/detail?id=1146526446","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146526446?lang=zh_cn&edition=full","pubTime":"2026-07-17 21:30","pubTimestamp":1784295043,"startTime":"0","endTime":"0","summary":"中国中药控股有限公司于2026年7月17日在香港发布公告，披露最新董事名单及其在董事会各专门委员会中的任职情况。董事会下设审核委员会、薪酬与考核委员会、提名委员会及战略委员会共4个专门委员会。郭晋红担任提名委员会主席及战略委员会主席。余梓山在四个委员会均任委员。公司表示，上述董事会及委员会安排已于公告日生效。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00570"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113490120","title":"中国中药（00570）高层调整：郭晋红接任董事会主席，杨军退休卸任","url":"https://stock-news.laohu8.com/highlight/detail?id=1113490120","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1113490120?lang=zh_cn&edition=full","pubTime":"2026-07-17 21:30","pubTimestamp":1784295032,"startTime":"0","endTime":"0","summary":"中国中药控股有限公司7月17日公告，公司董事会已于当日通过决议，完成多个核心职位的人事调整。郭晋红将任职至其获委任后的公司首次股东周年大会，届时可获选连任。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00570"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184362736","title":"预期中期业绩受挫，中国中药旗下中成药、药材等业务收入与盈利能力下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=1184362736","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184362736?lang=zh_cn&edition=full","pubTime":"2026-07-17 21:27","pubTimestamp":1784294834,"startTime":"0","endTime":"0","summary":"中国中药控股有限公司近期发布业绩预告，预计其中期业绩将受到不利影响。主要原因在于公司核心业务板块——中成药、中药材及其他相关业务的营业收入与整体盈利能力出现下滑。\n具体而言，在中成药业务领域，市场环境变化及行业竞争加剧对产品销售和利润空间构成了压力。与此同时，中药材业务也面临类似挑战，可能受到原材料价格波动、供应链因素或需求端变化的影响。这些因素共同导致了公司相关业务收入的减少与盈利能力的收缩。\n公司此次业绩预告反映了其在当前市场周期中所面临的阶段性困难。投资者将密切关注公司后续为应对挑战、改善经营状况所可能采取的战略调整与措施。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1606","BK1191","00570","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652285495","title":"中国中药(00570.HK)：郭晋红获委任为执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2652285495","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652285495?lang=zh_cn&edition=full","pubTime":"2026-07-17 21:23","pubTimestamp":1784294628,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","BK1515","BK1606","00570"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162468224","title":"中国中药控股有限公司 - 杨军先生辞任执行董事及董事会主席，即时生效","url":"https://stock-news.laohu8.com/highlight/detail?id=1162468224","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162468224?lang=zh_cn&edition=full","pubTime":"2026-07-17 21:22","pubTimestamp":1784294522,"startTime":"0","endTime":"0","summary":"中国中药控股有限公司宣布，杨军先生已辞任公司执行董事及董事会主席职务，该辞任自公告之日起即时生效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","00570","BK1606","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651584492","title":"【券商聚焦】光大证券：议优先布局经营稳健、业绩扎实或者股息类中药标的","url":"https://stock-news.laohu8.com/highlight/detail?id=2651584492","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651584492?lang=zh_cn&edition=full","pubTime":"2026-07-16 08:54","pubTimestamp":1784163265,"startTime":"0","endTime":"0","summary":"金吾财讯 | 光大证券研究指，近期，中药板块持续上涨，主要受到市场避险、政策利好、业绩催化和估值底部等多重因素共同推动，中期配置价值显著，后市偏乐观。建议优先布局经营稳健、业绩扎实或者高股息类中药标的。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985990","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03613","BK1606","02161","BK1515","BK4585","BK0276","02273","BK1219","BK4588","BK0183","601788","BK1147","BK0028","03320","01643","BK0188","VIG","02877","06178","BK1197","BK1191","BK1564","00570","KCE","00874","BK1570","BK0012","BK1521"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112804895","title":"中国中药更新2026年6月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1112804895","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1112804895?lang=zh_cn&edition=full","pubTime":"2026-07-02 16:50","pubTimestamp":1782982201,"startTime":"0","endTime":"0","summary":"中国中药（股票代码：00570）于2026年7月2日发布截至2026年6月30日的股份变动月报表。公告显示，公司截至本月底已发行普通股5,035,801,852股，未持有库藏股份，且与上月底持股数量相比无新增发行或回购、注销变动。\n报告期内，公司无股份期权或股权激励计划相关操作，也未进行任何购回股份或赎回股份行为。此外，公司对外确认，截至本月末，已满足适用的最低公众持股量要求。公司在本期内法定/注册股本无发生变动。\n本次月报表由公司秘书伍秀薇签署，公司表示将继续严格遵守香港联交所《上市规则》及相关法律法规的相关要求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00570"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.china-tcm.com.cn","stockEarnings":[{"period":"1week","weight":-0.0041},{"period":"1month","weight":-0.129},{"period":"3month","weight":-0.0933},{"period":"6month","weight":-0.3324},{"period":"1year","weight":-0.4895},{"period":"ytd","weight":-0.4187}],"compareEarnings":[{"period":"1week","weight":-0.0097},{"period":"1month","weight":-0.0446},{"period":"3month","weight":0.0811},{"period":"6month","weight":-0.0177},{"period":"1year","weight":-0.0746},{"period":"ytd","weight":-0.0437}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"中国中药控股有限公司是一家主要从事中药制造及销售的投资控股公司。该公司通过四个分部运营业务。一方分部主要从事中药配方颗粒、中药大健康产品及中药饮片的生产及销售。天江分部主要从事中药配方颗粒、中药饮片及中药大健康产品的生产及销售。该分部还透过其线下医疗机构提供中医药相关的医疗保健解决方案,包括中医问诊诊断、中医理疗、中药配方颗粒处方药等产品。同济堂分部主要从事中药配方颗粒、中药饮片及中成药的生产及销售。该分部还从事大健康产业的各种大健康产品的生产及销售及透过线下医疗机构提供中药医疗保健解决方案。","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":-0.00955},{"month":2,"riseRate":0.666667,"avgChangeRate":0.108445},{"month":3,"riseRate":0.333333,"avgChangeRate":0.008801},{"month":4,"riseRate":0.393939,"avgChangeRate":0.016282},{"month":5,"riseRate":0.558824,"avgChangeRate":0.076578},{"month":6,"riseRate":0.411765,"avgChangeRate":-0.020802},{"month":7,"riseRate":0.5,"avgChangeRate":0.003537},{"month":8,"riseRate":0.352941,"avgChangeRate":-0.000616},{"month":9,"riseRate":0.5,"avgChangeRate":-0.023139},{"month":10,"riseRate":0.484848,"avgChangeRate":-0.01946},{"month":11,"riseRate":0.454545,"avgChangeRate":0.032},{"month":12,"riseRate":0.454545,"avgChangeRate":0.006851}],"exchange":"SEHK","name":"中国中药","nameEN":"TRAD CHI MED"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"中国中药(00570)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供中国中药(00570)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"中国中药,00570,中国中药股票,中国中药股票老虎,中国中药股票老虎国际,中国中药行情,中国中药股票行情,中国中药股价,中国中药股市,中国中药股票价格,中国中药股票交易,中国中药股票购买,中国中药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"中国中药(00570)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供中国中药(00570)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}